Refine by
Cellular Therapies Articles & Analysis
488 news found
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), an autologous (patient’s own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida’s SB 1768, ...
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development. These diagnostic services are designed to support the scientific community in identifying, understanding, and ultimately treating rare diseases that ...
This year Protheragen-ING has extended its portfolio of Active Pharmaceutical Ingredients (APIs) to include several hundred new varieties, catering to a broad spectrum of therapeutic needs such as anti-tumor, hypoglycemic, antipsychotic, bronchiectasis, and antihypertensive treatments. Such growth represents Protheragen-ING’s commitment to support researchers worldwide in their quest of ...
Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery. Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, underscoring the urgent need for ...
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease. Glaucoma is a group of eye conditions that damage the optic nerve, often ...
In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. Specializing in complex biologic formulations, Biologics & Biosimilars service team of CD Formulation is revolutionizing how drug conjugate products are conceptualized and produced, ...
Idiopathic pulmonary fibrosis (IPF) remains a devastating condition with limited treatment options, often leading to a grim prognosis. However, a recent study by Milman-Krentsis (2024) offers a beacon of hope, demonstrating the potential of lung cell transplantation as a therapeutic intervention for lung fibrosis. Utilizing two distinct mouse models—one treated with bleomycin and another ...
Advanced Instruments, a leading provider of analytical instruments and services for clinical and biopharmaceutical laboratories, is proud to announce the expansion of its Artel portfolio’s direct presence in Austria, France, Germany, and Switzerland. This strategic move underscores Advanced Instruments’ commitment to providing unparalleled access to their liquid volume verification ...
Almost anyone with a weakened or suppressed immune system could be at a heightened risk of developing an invasive mold infection (IMI). Two of the most common IMIs include invasive aspergillosis and invasive mucormycosis. The Centers for Disease Control and Prevention (CDC) warns that IMIs can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to ...
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an ...
ByTempus
Longeveron's foundation in cutting-edge cellular therapy research, coupled with the promise of Lomecel-BTM, positions us to profoundly impact patients' lives for the better by addressing numerous unmet medical needs with U.S. market potential opportunities of up to approximately $10-$18 billion. ...
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. CELLINK Vivoink is optimized for superior printability, mechanical stability, and ...
ByCELLINK
Anyone with a weakened or suppressed immune system could be at heightened risk of developing an invasive mold infection. The Centers for Disease Control and Prevention (CDC) warns that these types of infections can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to advise physicians to keep invasive mold infections in mind when treating people ...
Our experienced team of CAR-T specialists can not only develop cutting-edge CAR-T therapies using advanced technologies, but also perform related biochemical evaluations." In the rapidly evolving field of drug delivery systems, novel therapies are continuously being developed to enhance the effectiveness and precision of treatment. ...
Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen ...
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. The capacity of cancer cells for aerobic glycolysis is 20–30 times greater than that of normal ...